This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

'Fast Money' Recap: Next Stop, S&P 2,100?

Robyn Karnauskas, biotechnology analyst at Deutsche Bank, said the big theme among biotech companies is creating drugs that address big markets, such as the different liver diseases. She likes Achillion Pharmaceuticals (ACHN) , which is developing treatments for Hepatitis C. A similar peer to ACHN is Idenix Pharmaceuticals (IDIX) , which was recently purchased by Merck (MRK)

She also likes Intercept Pharmaceuticals (ICPT) , which is developing a treatment for nonalcoholic steatohepatitis. Arrowhead Research (ARWR) could also be an attractive takeover target if its Hepatitis B drug data, which is scheduled to be released this fall, is positive. 

Najarian said stocks like Amgen (AMGN) and Celgene have reasonable valuations and strong growth. He likes them on the long side. 

Grasso reminded investors that biotech stocks can be volatile. He suggested using the iShares Nasdaq Biotechnology ETF (IBB) to diversify the risks. 

Amazon (AMZN) announced that it will purchase Twitch for $970 million. Grasso said he likes the company's move into the gaming and video segment. 

Burger King Worldwide (BKW) is in talks to purchase Tim Hortons (THI) and both stocks climbed roughly 20%. Seymour said this is a great deal for Tim Hortons and will benefit Burger King from a tax perspective. Najarian said it will help BKW boost its breakfast and coffee segments as well its exposure in Canada. 

Adami said he still finds Burger King cheap, even after Monday's rally. If forced to choose between Burger King and McDonald's (MCD) as investment, Grasso is a buyer of McDonald's. 

Dennis Gartman, editor and publisher of The Gartman Letter, was a guest on the show. Despite WTI crude prices falling 12% in the past two months, he said there is more downside ahead, possibly to $85. Until the front month contracts stop trading at lower prices than the back month contracts, the commodity is unlikely to rally. 

However, Gartman is a buyer of natural gas, saying that bad news is no longer sending the commodity lower -- a sign that a bottom has been put in. He argued that below $4.00 BTU, natural gas seems attractive. Turning to soft commodities, he said grain rallies should be sold. But due to the bountiful harvest, consumer should enjoy lower meat and crop prices in the future. 

Read More: Galena Fires CEO Ahn, Offers No Parting Gifts

Najarian said companies that have both oil and gas operations may be able to withstand falling crude oil prices. 

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%
TSLA $226.03 0.00%
YHOO $42.51 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs